FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000291890> ?p ?o ?g. }

• W2000291890 endingPage "850" @default.
• W2000291890 startingPage "845" @default.
• W2000291890 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Mar 2000RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER THOMAS M. PISANSKY, TIMOTHY F. KOZELSKY, ROBERT P. MYERS, DAVID W. HILLMAN, MICHAEL L. BLUTE, STEVEN J. BUSKIRK, JOHN C. CHEVILLE, ROBERT G. FERRIGNI, and STEVEN E. SCHILD THOMAS M. PISANSKYTHOMAS M. PISANSKY More articles by this author , TIMOTHY F. KOZELSKYTIMOTHY F. KOZELSKY More articles by this author , ROBERT P. MYERSROBERT P. MYERS More articles by this author , DAVID W. HILLMANDAVID W. HILLMAN More articles by this author , MICHAEL L. BLUTEMICHAEL L. BLUTE More articles by this author , STEVEN J. BUSKIRKSTEVEN J. BUSKIRK More articles by this author , JOHN C. CHEVILLEJOHN C. CHEVILLE More articles by this author , ROBERT G. FERRIGNIROBERT G. FERRIGNI More articles by this author , and STEVEN E. SCHILDSTEVEN E. SCHILD More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67817-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Elevated serum prostate specific antigen (PSA) may be the initial and only indication of disease recurrence after prostatectomy for prostate cancer. External beam radiotherapy may be given in this setting in an attempt to eradicate the disease but therapeutic outcomes after this approach require further description. We describe the intermediate term outcome in a large group of patients treated with radiotherapy and identify pre-therapy factors associated with disease outcome. Materials and Methods: We retrospectively studied a cohort of 166 consecutive patients treated with radiotherapy between July 1987 and May 1996. The Kaplan-Meier method was used to describe patient outcome for the overall study group, and statistical associations of pre-therapy variables with outcome were sought to identify predictive factors. Results: At a median followup of 52 months 46% (95% confidence interval 38 to 55) of patients were expected to be free of biochemical relapse 5 years after radiotherapy. Multivariate analysis identified pathological classification (seminal vesicle invasion), tumor grade and pre-radiotherapy serum PSA as independent factors associated with biochemical relapse. Although in 1 of 6 patients a chronic complication was attributed to radiotherapy, it was often mild and self-limited in nature. Conclusions: In our current series approximately half of the patients treated with radiotherapy for an isolated elevation of serum PSA after prostatectomy were free of biochemical relapse at 5 years of followup. Radiotherapy may be given in this setting with modest long-term morbidity. References 1 : National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Committee on Cancer. J Urol1994; 152: 1817. Link, Google Scholar 2 : Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol1994; 151: 1575. Link, Google Scholar 3 : Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology1995; 45: 1022. Google Scholar 4 : The efficacy of post-prostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys1995; 32: 317. Google Scholar 5 : Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology1996; 47: 232. Google Scholar 6 : Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer1996; 78: 1254. Google Scholar 7 : The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol1996; 156: 1725. Link, Google Scholar 8 : Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys1997; 39: 681. Google Scholar 9 : Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol1997; 158: 1436. Link, Google Scholar 10 : Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys1997; 38: 731. Google Scholar 11 : Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol1998; 159: 173. Link, Google Scholar 12 : Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am1998; 4: 324. Google Scholar 13 Prostate. In: . Philadelphia: Lippincott-Raven1997: 219. Google Scholar 14 : Pathologic differentiation and prognosis of prostatic carcinoma. JAMA1969; 209: 1701. Google Scholar 15 : Nonparametric estimation from incomplete observations. J Am Stat Assoc1958; 53: 457. Google Scholar 16 : Regression models and life tables. J Roy Stat Soc1972; 34: 187. Google Scholar 17 : Prostate specific antigen and local recurrence after radical prostatectomy. J Urol1990; 144: 921. Link, Google Scholar 18 : Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol1995; 153: 1011. Link, Google Scholar 19 : Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology1996; 47: 225. Google Scholar 20 Decision trees and management guidelinesPatterns of Care Committees. Semin Radiat Oncol1997; 7: 163. Google Scholar 21 : Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys1998; 41: 735. Google Scholar 22 : Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst1997; 89: 1498. Google Scholar 23 : Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol1998; 16: 284. Google Scholar 24 : 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol1998; 159: 2041. Link, Google Scholar From the Division of Radiation Oncology, Departments of Urology, and Laboratory Medicine and Pathology, and Cancer Center Statistical Unit, Mayo Clinic, Rochester, Minnesota, Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, and Departments of Urology and Radiation Oncology, Mayo Clinic, Scottsdale, Arizona© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited BySobol I, Zaid H, Haloi R, Mynderse L, Froemming A, Lowe V, Davis B, Kwon E and Karnes R (2018) Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with 11C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance ImagingJournal of Urology, VOL. 197, NO. 1, (129-134), Online publication date: 1-Jan-2017.Boorjian S, Karnes R, Crispen P, Rangel L, Bergstralh E and Blute M (2018) Radiation Therapy After Radical Prostatectomy: Impact on Metastasis and SurvivalJournal of Urology, VOL. 182, NO. 6, (2708-2715), Online publication date: 1-Dec-2009.Buskirk S, Pisansky T, Schild S, Macdonald O, Wehle M, Kozelsky T, Collie A, Ferrigni R, Myers R, Prussak K, Heckman M, Crook J, Parker A and Igel T (2018) Salvage Radiotherapy for Isolated Prostate Specific Antigen Increase After Radical Prostatectomy: Evaluation of Prognostic Factors and Creation of a Prognostic Scoring SystemJournal of Urology, VOL. 176, NO. 3, (985-990), Online publication date: 1-Sep-2006.CHROUSER K, LEIBOVICH B, SWEAT S, LARSON D, DAVIS B, TRAN N, ZINCKE H and BLUTE M (2018) URINARY FISTULAS FOLLOWING EXTERNAL RADIATION OR PERMANENT BRACHYTHERAPY FOR THE TREATMENT OF PROSTATE CANCERJournal of Urology, VOL. 173, NO. 6, (1953-1957), Online publication date: 1-Jun-2005.PAZONA J, HAN M, HAWKINS S, ROEHL K and CATALONA W (2018) SALVAGE RADIATION THERAPY FOR PROSTATE SPECIFIC ANTIGEN PROGRESSION FOLLOWING RADICAL PROSTATECTOMY: 10-YEAR OUTCOME ESTIMATESJournal of Urology, VOL. 174, NO. 4 Part 1, (1282-1286), Online publication date: 1-Oct-2005.BROOKS J, ALBERT P, WILDER R, GANT D, McLEOD D and POGGI M (2018) LONG-TERM SALVAGE RADIOTHERAPY OUTCOME AFTER RADICAL PROSTATECTOMY AND RELAPSE PREDICTORSJournal of Urology, VOL. 174, NO. 6, (2204-2208), Online publication date: 1-Dec-2005. (2018) RE: NEOADJUVANT HORMONE THERAPY BEFORE SALVAGE RADIOTHERAPY FOR AN INCREASING POST-RADICAL PROSTATECTOMY SERUM PROSTATE SPECIFIC ANTIGEN LEVELJournal of Urology, VOL. 171, NO. 2, (809-810), Online publication date: 1-Feb-2004.MATSUI Y, ICHIOKA K, TERADA N, YOSHIMURA K, TERAI A, DODO Y and ARAI Y (2018) Impact of Volume Weighted Mean Nuclear Volume on Outcomes Following Salvage Radiation Therapy After Radical ProstatectomyJournal of Urology, VOL. 171, NO. 2, (687-691), Online publication date: 1-Feb-2004.AKDUMAN B and CRAWFORD E (2018) The Management of High Risk Prostate CancerJournal of Urology, VOL. 169, NO. 6, (1993-1998), Online publication date: 1-Jun-2003.TIGUERT R, RIGAUD J, LACOMBE L, LAVERDIÈRE J and FRADET Y (2018) Neoadjuvant Hormone Therapy Before Salvage Radiotherapy for an Increasing Post-radical Prostatectomy Serum Prostate Specific Antigen LevelJournal of Urology, VOL. 170, NO. 2, (447-450), Online publication date: 1-Aug-2003.MACDONALD O, SCHILD S, VORA S, ANDREWS P, FERRIGNI R, NOVICKI D, SWANSON S and WONG W (2018) Radiotherapy for Men With Isolated Increase in Serum Prostate Specific Antigen After Radical ProstatectomyJournal of Urology, VOL. 170, NO. 5, (1833-1837), Online publication date: 1-Nov-2003. Volume 163Issue 3March 2000Page: 845-850 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsprostateprostatectomyradiotherapyprostate-specific antigenprostatic neoplasmsMetricsAuthor Information THOMAS M. PISANSKY More articles by this author TIMOTHY F. KOZELSKY More articles by this author ROBERT P. MYERS More articles by this author DAVID W. HILLMAN More articles by this author MICHAEL L. BLUTE More articles by this author STEVEN J. BUSKIRK More articles by this author JOHN C. CHEVILLE More articles by this author ROBERT G. FERRIGNI More articles by this author STEVEN E. SCHILD More articles by this author Expand All Advertisement PDF DownloadLoading ..." @default.
• W2000291890 created "2016-06-24" @default.
• W2000291890 creator A5004092928 @default.
• W2000291890 creator A5013219986 @default.
• W2000291890 creator A5019283638 @default.
• W2000291890 creator A5019525982 @default.
• W2000291890 creator A5062848479 @default.
• W2000291890 creator A5064685843 @default.
• W2000291890 creator A5082725102 @default.
• W2000291890 creator A5086710213 @default.
• W2000291890 creator A5087508472 @default.
• W2000291890 date "2000-03-01" @default.
• W2000291890 modified "2023-10-17" @default.
• W2000291890 title "RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCER" @default.
• W2000291890 cites W1252490173 @default.
• W2000291890 cites W174894273 @default.
• W2000291890 cites W1971735866 @default.
• W2000291890 cites W1991002711 @default.
• W2000291890 cites W1999219360 @default.
• W2000291890 cites W2009576939 @default.
• W2000291890 cites W2021818851 @default.
• W2000291890 cites W2046873144 @default.
• W2000291890 cites W2050170590 @default.
• W2000291890 cites W2062869963 @default.
• W2000291890 cites W2077015435 @default.
• W2000291890 cites W2089372512 @default.
• W2000291890 cites W2090292364 @default.
• W2000291890 cites W2120160519 @default.
• W2000291890 cites W2125835130 @default.
• W2000291890 cites W2151976293 @default.
• W2000291890 cites W2230262546 @default.
• W2000291890 cites W2418143924 @default.
• W2000291890 cites W3041047318 @default.
• W2000291890 cites W4239741083 @default.
• W2000291890 cites W4242246035 @default.
• W2000291890 doi "https://doi.org/10.1016/s0022-5347(05)67817-2" @default.
• W2000291890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10992405" @default.
• W2000291890 hasPublicationYear "2000" @default.
• W2000291890 type Work @default.
• W2000291890 sameAs 2000291890 @default.
• W2000291890 citedByCount "195" @default.
• W2000291890 countsByYear W20002918902012 @default.
• W2000291890 countsByYear W20002918902013 @default.
• W2000291890 countsByYear W20002918902014 @default.
• W2000291890 countsByYear W20002918902015 @default.
• W2000291890 countsByYear W20002918902016 @default.
• W2000291890 countsByYear W20002918902017 @default.
• W2000291890 countsByYear W20002918902018 @default.
• W2000291890 countsByYear W20002918902019 @default.
• W2000291890 countsByYear W20002918902020 @default.
• W2000291890 countsByYear W20002918902021 @default.
• W2000291890 countsByYear W20002918902022 @default.
• W2000291890 countsByYear W20002918902023 @default.
• W2000291890 crossrefType "journal-article" @default.
• W2000291890 hasAuthorship W2000291890A5004092928 @default.
• W2000291890 hasAuthorship W2000291890A5013219986 @default.
• W2000291890 hasAuthorship W2000291890A5019283638 @default.
• W2000291890 hasAuthorship W2000291890A5019525982 @default.
• W2000291890 hasAuthorship W2000291890A5062848479 @default.
• W2000291890 hasAuthorship W2000291890A5064685843 @default.
• W2000291890 hasAuthorship W2000291890A5082725102 @default.
• W2000291890 hasAuthorship W2000291890A5086710213 @default.
• W2000291890 hasAuthorship W2000291890A5087508472 @default.
• W2000291890 hasConcept C121608353 @default.
• W2000291890 hasConcept C126322002 @default.
• W2000291890 hasConcept C126894567 @default.
• W2000291890 hasConcept C143998085 @default.
• W2000291890 hasConcept C2776235491 @default.
• W2000291890 hasConcept C2779466945 @default.
• W2000291890 hasConcept C2780192828 @default.
• W2000291890 hasConcept C2781406297 @default.
• W2000291890 hasConcept C509974204 @default.
• W2000291890 hasConcept C71924100 @default.
• W2000291890 hasConceptScore W2000291890C121608353 @default.
• W2000291890 hasConceptScore W2000291890C126322002 @default.
• W2000291890 hasConceptScore W2000291890C126894567 @default.
• W2000291890 hasConceptScore W2000291890C143998085 @default.
• W2000291890 hasConceptScore W2000291890C2776235491 @default.
• W2000291890 hasConceptScore W2000291890C2779466945 @default.
• W2000291890 hasConceptScore W2000291890C2780192828 @default.
• W2000291890 hasConceptScore W2000291890C2781406297 @default.
• W2000291890 hasConceptScore W2000291890C509974204 @default.
• W2000291890 hasConceptScore W2000291890C71924100 @default.
• W2000291890 hasIssue "3" @default.
• W2000291890 hasLocation W20002918901 @default.
• W2000291890 hasLocation W20002918902 @default.
• W2000291890 hasOpenAccess W2000291890 @default.
• W2000291890 hasPrimaryLocation W20002918901 @default.
• W2000291890 hasRelatedWork W1967410728 @default.
• W2000291890 hasRelatedWork W1980188241 @default.
• W2000291890 hasRelatedWork W2038565121 @default.
• W2000291890 hasRelatedWork W2093197441 @default.
• W2000291890 hasRelatedWork W2111952090 @default.
• W2000291890 hasRelatedWork W2402249956 @default.
• W2000291890 hasRelatedWork W2897445903 @default.
• W2000291890 hasRelatedWork W3129209394 @default.
• W2000291890 hasRelatedWork W3150909901 @default.
• W2000291890 hasRelatedWork W4241710403 @default.

• next